The Second-Window Infrared Fluorescence Triband Imager (SWIFTI) was originally developed to help treat ovarian cancer. However, the probe developed at MIT can be targeted to other cancer types, so its impact can have far-reaching consequences for cancer treatments in general. SWIFTI enables surgeons to quickly and accurately distinguish micro-tumors from healthy tissue. The surgical team can use SWIFTI to scan the entire surgical field for both large and small tumors. A specially formulated fluorescent probe (a chemical that selectively binds to tumors and makes them “glow” in the second near-infrared window [NIR-II] band when struck by a laser) makes tumors appear bright in the SWIFTI display.